Connection

Raymond DuBois to Humans

Back to Details
This is a "connection" page, showing publications Raymond DuBois has written about Humans.
Raymond DuBois
Connection Strength
1.408
Humans
  1. Role of Prostaglandin E2 in the Progression of Gastrointestinal Cancer. Cancer Prev Res (Phila). 2022 06 02; 15(6):355-363.
    View in: PubMed
    Score: 0.031
  2. The COX-2-PGE2 Pathway Promotes Tumor Evasion in Colorectal Adenomas. Cancer Prev Res (Phila). 2022 05 03; 15(5):285-296.
    View in: PubMed
    Score: 0.031
  3. The First Lady Presses for Cancer Screening to Get Back On Track. Cancer Prev Res (Phila). 2022 01; 15(1):1-2.
    View in: PubMed
    Score: 0.030
  4. The Urgent Need for Expanded Cancer Screening. Cancer Prev Res (Phila). 2021 12; 14(12):1053-1054.
    View in: PubMed
    Score: 0.029
  5. Cyclooxygenases and Prostaglandins in Tumor Immunology and Microenvironment of Gastrointestinal Cancer. Gastroenterology. 2021 12; 161(6):1813-1829.
    View in: PubMed
    Score: 0.029
  6. Mutant APC promotes tumor immune evasion via PD-L1 in colorectal cancer. Oncogene. 2021 10; 40(41):5984-5992.
    View in: PubMed
    Score: 0.029
  7. COVID-19, Cancer Care and Prevention. Cancer Prev Res (Phila). 2020 11; 13(11):889-892.
    View in: PubMed
    Score: 0.027
  8. Fibroblasts fuel intestinal tumorigenesis. Cell Res. 2020 08; 30(8):635-636.
    View in: PubMed
    Score: 0.027
  9. Prostaglandin E2 Induces miR675-5p to Promote Colorectal Tumor Metastasis via Modulation of p53 Expression. Gastroenterology. 2020 03; 158(4):971-984.e10.
    View in: PubMed
    Score: 0.026
  10. PPARd Mediates the Effect of Dietary Fat in Promoting Colorectal Cancer Metastasis. Cancer Res. 2019 09 01; 79(17):4480-4490.
    View in: PubMed
    Score: 0.025
  11. Role of prostanoids in gastrointestinal cancer. J Clin Invest. 2018 07 02; 128(7):2732-2742.
    View in: PubMed
    Score: 0.023
  12. CXCL1 Is Critical for Premetastatic Niche Formation and Metastasis in Colorectal Cancer. Cancer Res. 2017 07 01; 77(13):3655-3665.
    View in: PubMed
    Score: 0.022
  13. Kr?ppel-Like Factor 12 Promotes Colorectal Cancer Growth through Early Growth Response Protein 1. PLoS One. 2016; 11(7):e0159899.
    View in: PubMed
    Score: 0.020
  14. The Role of Prostaglandin E(2) in Tumor-Associated Immunosuppression. Trends Mol Med. 2016 Jan; 22(1):1-3.
    View in: PubMed
    Score: 0.020
  15. Immunosuppression associated with chronic inflammation in the tumor microenvironment. Carcinogenesis. 2015 Oct; 36(10):1085-93.
    View in: PubMed
    Score: 0.019
  16. Prostaglandin E2 Promotes Colorectal Cancer Stem Cell Expansion and Metastasis in Mice. Gastroenterology. 2015 Dec; 149(7):1884-1895.e4.
    View in: PubMed
    Score: 0.019
  17. The Jeremiah Metzger Lecture: Inflammation, Immune Modulators, and Chronic Disease. Trans Am Clin Climatol Assoc. 2015; 126:230-6.
    View in: PubMed
    Score: 0.018
  18. CG100649, a novel COX-2 inhibitor, inhibits colorectal adenoma and carcinoma growth in mouse models. Invest New Drugs. 2014 Dec; 32(6):1105-1112.
    View in: PubMed
    Score: 0.018
  19. Peroxisome proliferator-activated receptor d promotes colonic inflammation and tumor growth. Proc Natl Acad Sci U S A. 2014 May 13; 111(19):7084-9.
    View in: PubMed
    Score: 0.018
  20. Role of inflammation and inflammatory mediators in colorectal cancer. Trans Am Clin Climatol Assoc. 2014; 125:358-72; discussion 372-3.
    View in: PubMed
    Score: 0.017
  21. CXCR2-expressing myeloid-derived suppressor cells are essential to promote colitis-associated tumorigenesis. Cancer Cell. 2013 Nov 11; 24(5):631-44.
    View in: PubMed
    Score: 0.017
  22. An inflammatory mediator, prostaglandin E2, in colorectal cancer. Cancer J. 2013 Nov-Dec; 19(6):502-10.
    View in: PubMed
    Score: 0.017
  23. HIG2 promotes colorectal cancer progression via hypoxia-dependent and independent pathways. Cancer Lett. 2013 Dec 01; 341(2):159-65.
    View in: PubMed
    Score: 0.017
  24. Urinary PGE-M: a promising cancer biomarker. Cancer Prev Res (Phila). 2013 Jun; 6(6):507-10.
    View in: PubMed
    Score: 0.016
  25. PPAR? agonists target aromatase via both PGE2 and BRCA1. Cancer Prev Res (Phila). 2012 Oct; 5(10):1169-72.
    View in: PubMed
    Score: 0.016
  26. The role of anti-inflammatory drugs in colorectal cancer. Annu Rev Med. 2013; 64:131-44.
    View in: PubMed
    Score: 0.016
  27. Metronomic topotecan for colorectal cancer: a promising new option. Gut. 2013 Feb; 62(2):190-1.
    View in: PubMed
    Score: 0.015
  28. The role of the PGE2-aromatase pathway in obesity-associated breast inflammation. Cancer Discov. 2012 Apr; 2(4):308-10.
    View in: PubMed
    Score: 0.015
  29. Associations between obesity and cancer: the role of fatty acid synthase. J Natl Cancer Inst. 2012 Mar 07; 104(5):343-5.
    View in: PubMed
    Score: 0.015
  30. Overview of the AACR Clinical and Translational Cancer Research Think Tank meeting. Clin Cancer Res. 2012 Feb 01; 18(3):607-11.
    View in: PubMed
    Score: 0.015
  31. Prostaglandin E2 promotes intestinal tumor growth via DNA methylation. Nat Med. 2012 Jan 22; 18(2):224-6.
    View in: PubMed
    Score: 0.015
  32. Epoxyeicosatrienoic acids: a double-edged sword in cardiovascular diseases and cancer. J Clin Invest. 2012 Jan; 122(1):19-22.
    View in: PubMed
    Score: 0.015
  33. ANGPTL4 induction by prostaglandin E2 under hypoxic conditions promotes colorectal cancer progression. Cancer Res. 2011 Nov 15; 71(22):7010-20.
    View in: PubMed
    Score: 0.015
  34. Nuclear orphan receptor NR4A2 modulates fatty acid oxidation pathways in colorectal cancer. J Biol Chem. 2011 Aug 26; 286(34):30003-9.
    View in: PubMed
    Score: 0.014
  35. Therapeutic potential of peroxisome proliferator-activated receptors in chronic inflammation and colorectal cancer. Gastroenterol Clin North Am. 2010 Sep; 39(3):697-707.
    View in: PubMed
    Score: 0.014
  36. Human enhancer of filamentation 1 Is a mediator of hypoxia-inducible factor-1alpha-mediated migration in colorectal carcinoma cells. Cancer Res. 2010 May 15; 70(10):4054-63.
    View in: PubMed
    Score: 0.013
  37. Cyclooxygenase-2 and cancer treatment: understanding the risk should be worth the reward. Clin Cancer Res. 2010 Mar 01; 16(5):1384-90.
    View in: PubMed
    Score: 0.013
  38. Eicosanoids and cancer. Nat Rev Cancer. 2010 Mar; 10(3):181-93.
    View in: PubMed
    Score: 0.013
  39. HEF1 is a crucial mediator of the proliferative effects of prostaglandin E(2) on colon cancer cells. Cancer Res. 2010 Jan 15; 70(2):824-31.
    View in: PubMed
    Score: 0.013
  40. Tailoring treatment in translational cancer research: An Interview with Raymond N. DuBois, MD, PhD. Interviewed by Elaine Musgrave. Clin Transl Sci. 2009 Jun; 2(3):178-9.
    View in: PubMed
    Score: 0.012
  41. New, long-term insights from the Adenoma Prevention with Celecoxib Trial on a promising but troubled class of drugs. Cancer Prev Res (Phila). 2009 Apr; 2(4):285-7.
    View in: PubMed
    Score: 0.012
  42. Repression of 15-hydroxyprostaglandin dehydrogenase involves histone deacetylase 2 and snail in colorectal cancer. Cancer Res. 2008 Nov 15; 68(22):9331-7.
    View in: PubMed
    Score: 0.012
  43. Pro-inflammatory prostaglandins and progression of colorectal cancer. Cancer Lett. 2008 Aug 28; 267(2):197-203.
    View in: PubMed
    Score: 0.012
  44. Regulation of prostaglandin transporters in colorectal neoplasia. Cancer Prev Res (Phila). 2008 Jul; 1(2):93-9.
    View in: PubMed
    Score: 0.011
  45. Targeting cyclooxygenase-2 and the epidermal growth factor receptor for the prevention and treatment of intestinal cancer. Cancer Res. 2007 Oct 01; 67(19):9380-8.
    View in: PubMed
    Score: 0.011
  46. Inflammatory mediators and nuclear receptor signaling in colorectal cancer. Cell Cycle. 2007 Mar 15; 6(6):682-5.
    View in: PubMed
    Score: 0.011
  47. NSAIDs and cancer prevention: targets downstream of COX-2. Annu Rev Med. 2007; 58:239-52.
    View in: PubMed
    Score: 0.011
  48. Measurement of eicosanoids in cancer tissues. Methods Enzymol. 2007; 433:27-50.
    View in: PubMed
    Score: 0.011
  49. Crosstalk between peroxisome proliferator-activated receptor delta and VEGF stimulates cancer progression. Proc Natl Acad Sci U S A. 2006 Dec 12; 103(50):19069-74.
    View in: PubMed
    Score: 0.011
  50. Gene expression profiling following constitutive activation of MEK1 and transformation of rat intestinal epithelial cells. Mol Cancer. 2006 Nov 17; 5:63.
    View in: PubMed
    Score: 0.010
  51. Emerging roles of beta-arrestins. Cell Cycle. 2006 Sep; 5(18):2060-3.
    View in: PubMed
    Score: 0.010
  52. Repression of prostaglandin dehydrogenase by epidermal growth factor and snail increases prostaglandin E2 and promotes cancer progression. Cancer Res. 2006 Jul 01; 66(13):6649-56.
    View in: PubMed
    Score: 0.010
  53. Cyclooxygenase-2 selective inhibitors and prostate cancer: what is the clinical benefit? J Clin Oncol. 2006 Jun 20; 24(18):2691-3.
    View in: PubMed
    Score: 0.010
  54. Cancer prevention: strategy for the future. Carcinogenesis. 2006 Jun; 27(6):1126-7.
    View in: PubMed
    Score: 0.010
  55. CXCL1 induced by prostaglandin E2 promotes angiogenesis in colorectal cancer. J Exp Med. 2006 Apr 17; 203(4):941-51.
    View in: PubMed
    Score: 0.010
  56. NSAIDs and prostate cancer risk. Cancer J. 2006 Mar-Apr; 12(2):108-9.
    View in: PubMed
    Score: 0.010
  57. Role of beta-arrestin 1 in the metastatic progression of colorectal cancer. Proc Natl Acad Sci U S A. 2006 Jan 31; 103(5):1492-7.
    View in: PubMed
    Score: 0.010
  58. The COX-2 story: is any drug completely "safe?". Gastroenterology. 2006 Jan; 130(1):6.
    View in: PubMed
    Score: 0.010
  59. Connecting COX-2 and Wnt in cancer. Cancer Cell. 2006 Jan; 9(1):6-8.
    View in: PubMed
    Score: 0.010
  60. Ras up-regulation of cyclooxygenase-2. Methods Enzymol. 2006; 407:401-10.
    View in: PubMed
    Score: 0.010
  61. Prostaglandin E2 regulates the nuclear receptor NR4A2 in colorectal cancer. J Biol Chem. 2006 Feb 03; 281(5):2676-82.
    View in: PubMed
    Score: 0.010
  62. Inflammation in the genesis and perpetuation of cancer: summary and recommendations from a national cancer institute-sponsored meeting. Cancer Res. 2005 Oct 01; 65(19):8583-6.
    View in: PubMed
    Score: 0.010
  63. Mechanisms for the prevention of gastrointestinal cancer: the role of prostaglandin E2. Oncology. 2005; 69 Suppl 1:28-32.
    View in: PubMed
    Score: 0.010
  64. The role of prostaglandins and other eicosanoids in the gastrointestinal tract. Gastroenterology. 2005 May; 128(5):1445-61.
    View in: PubMed
    Score: 0.009
  65. COX-2: a molecular target for colorectal cancer prevention. J Clin Oncol. 2005 Apr 20; 23(12):2840-55.
    View in: PubMed
    Score: 0.009
  66. Mechanisms of disease: Inflammatory mediators and cancer prevention. Nat Clin Pract Oncol. 2005 Apr; 2(4):202-10.
    View in: PubMed
    Score: 0.009
  67. Cyclooxygenase-2 and epidermal growth factor receptor: pharmacologic targets for chemoprevention. J Clin Oncol. 2005 Jan 10; 23(2):254-66.
    View in: PubMed
    Score: 0.009
  68. WNT and cyclooxygenase-2 cross-talk accelerates adenoma growth. Cell Cycle. 2004 Dec; 3(12):1512-5.
    View in: PubMed
    Score: 0.009
  69. 15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. J Biol Chem. 2005 Feb 04; 280(5):3217-23.
    View in: PubMed
    Score: 0.009
  70. Prostaglandin E2 regulates the complement inhibitor CD55/decay-accelerating factor in colorectal cancer. J Biol Chem. 2005 Jan 07; 280(1):476-83.
    View in: PubMed
    Score: 0.009
  71. Disease prevention: the future is here. Gastroenterology. 2004 Nov; 127(5):1289.
    View in: PubMed
    Score: 0.009
  72. Prostaglandin E(2) promotes colorectal adenoma growth via transactivation of the nuclear peroxisome proliferator-activated receptor delta. Cancer Cell. 2004 Sep; 6(3):285-95.
    View in: PubMed
    Score: 0.009
  73. Cyclooxygenase as a target in lung cancer. Clin Cancer Res. 2004 Jun 15; 10(12 Pt 2):4266s-4269s.
    View in: PubMed
    Score: 0.009
  74. Aspirin and breast cancer prevention: the estrogen connection. JAMA. 2004 May 26; 291(20):2488-9.
    View in: PubMed
    Score: 0.009
  75. Cyclooxygenase-2 in lung carcinogenesis and chemoprevention: Roger S. Mitchell lecture. Chest. 2004 May; 125(5 Suppl):134S-40S.
    View in: PubMed
    Score: 0.009
  76. Cyclooxygenase-2 and gastrointestinal cancer. Cancer J. 2004 May-Jun; 10(3):145-52.
    View in: PubMed
    Score: 0.009
  77. COX-2 inhibition and colorectal cancer. Semin Oncol. 2004 Apr; 31(2 Suppl 7):12-21.
    View in: PubMed
    Score: 0.009
  78. Activation of nuclear hormone receptor peroxisome proliferator-activated receptor-delta accelerates intestinal adenoma growth. Nat Med. 2004 Mar; 10(3):245-7.
    View in: PubMed
    Score: 0.009
  79. Cyclooxygenase-2: a potential target in breast cancer. Semin Oncol. 2004 Feb; 31(1 Suppl 3):64-73.
    View in: PubMed
    Score: 0.009
  80. Cyclooxygenase 2-derived prostaglandin E2 regulates the angiogenic switch. Proc Natl Acad Sci U S A. 2004 Jan 13; 101(2):415-6.
    View in: PubMed
    Score: 0.009
  81. 15-LOX-1 inhibits p21 (Cip/WAF 1) expression by enhancing MEK-ERK 1/2 signaling in colon carcinoma cells. Prostaglandins Other Lipid Mediat. 2004 Jan; 73(1-2):111-22.
    View in: PubMed
    Score: 0.009
  82. The physician-scientist in gastroenterology. Gastroenterology. 2003 Sep; 125(3):652.
    View in: PubMed
    Score: 0.008
  83. Cyclooxygenase 2 (COX-2) as a target for therapy and noninvasive imaging. Mol Imaging Biol. 2003 Sep-Oct; 5(5):286-303.
    View in: PubMed
    Score: 0.008
  84. Will an aspirin a day keep the endoscope away? Gastroenterology. 2003 Aug; 125(2):612-4.
    View in: PubMed
    Score: 0.008
  85. Leukotriene A4 signaling, inflammation, and cancer. J Natl Cancer Inst. 2003 Jul 16; 95(14):1028-9.
    View in: PubMed
    Score: 0.008
  86. Prostaglandin E2 regulates cell migration via the intracellular activation of the epidermal growth factor receptor. J Biol Chem. 2003 Sep 12; 278(37):35451-7.
    View in: PubMed
    Score: 0.008
  87. Evaluation of the whole prostaglandin biosynthetic pathway in lung cancer. Clin Cancer Res. 2003 May; 9(5):1577-8.
    View in: PubMed
    Score: 0.008
  88. The cyclooxygenase-2 pathway as a target for treatment or prevention of cancer. Expert Opin Emerg Drugs. 2003 May; 8(1):1-7.
    View in: PubMed
    Score: 0.008
  89. Cyclooxygenase-1 is overexpressed and promotes angiogenic growth factor production in ovarian cancer. Cancer Res. 2003 Mar 01; 63(5):906-11.
    View in: PubMed
    Score: 0.008
  90. Peroxisome proliferator-activated receptor gamma-mediated differentiation: a mutation in colon cancer cells reveals divergent and cell type-specific mechanisms. J Biol Chem. 2003 Jun 20; 278(25):22669-77.
    View in: PubMed
    Score: 0.008
  91. The emerging role and potential of COX-2 inhibitors. Clin Adv Hematol Oncol. 2003 Feb; 1(2):97-8.
    View in: PubMed
    Score: 0.008
  92. Cyclooxygenase-2 and colorectal cancer. Prog Exp Tumor Res. 2003; 37:124-37.
    View in: PubMed
    Score: 0.008
  93. New agents for cancer prevention. J Natl Cancer Inst. 2002 Dec 04; 94(23):1732-3.
    View in: PubMed
    Score: 0.008
  94. Peroxisome proliferator-activated receptor gamma and transforming growth factor-beta pathways inhibit intestinal epithelial cell growth by regulating levels of TSC-22. J Biol Chem. 2003 Feb 28; 278(9):7431-8.
    View in: PubMed
    Score: 0.008
  95. The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission. Mol Cancer Res. 2022 Nov 03; 20(11):1591-1597.
    View in: PubMed
    Score: 0.008
  96. The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission. Mol Cancer Ther. 2022 Nov 03; 21(11):1625-1631.
    View in: PubMed
    Score: 0.008
  97. The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission. Cancer Epidemiol Biomarkers Prev. 2022 11 02; 31(11):1995-2001.
    View in: PubMed
    Score: 0.008
  98. The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission. Cancer Discov. 2022 Nov 02; 12(11):2475-2481.
    View in: PubMed
    Score: 0.008
  99. The AACR Journals: Advancing Progress Toward the AACR's 115-Year Mission. Clin Cancer Res. 2022 Nov 01; 28(21):4593-4599.
    View in: PubMed
    Score: 0.008
  100. Controversy: PPARgamma as a target for treatment of colorectal cancer. Am J Physiol Gastrointest Liver Physiol. 2002 Aug; 283(2):G266-9.
    View in: PubMed
    Score: 0.008
  101. Cyclooxygenase-2 inhibitor therapy for the prevention of esophageal adenocarcinoma in Barrett's esophagus. J Natl Cancer Inst. 2002 Mar 20; 94(6):406-7.
    View in: PubMed
    Score: 0.008
  102. COX-2: a target for colon cancer prevention. Annu Rev Pharmacol Toxicol. 2002; 42:55-80.
    View in: PubMed
    Score: 0.007
  103. Cyclooxygenase-2: a therapeutic target. Annu Rev Med. 2002; 53:35-57.
    View in: PubMed
    Score: 0.007
  104. AACR White Paper: Shaping the Future of Cancer Prevention - A Roadmap for Advancing Science and Public Health. Cancer Prev Res (Phila). 2018 12; 11(12):735-778.
    View in: PubMed
    Score: 0.006
  105. Changes in cancer cell metabolism revealed by direct sample analysis with MALDI mass spectrometry. PLoS One. 2013; 8(4):e61379.
    View in: PubMed
    Score: 0.004
  106. Prostaglandin E2 regulates pancreatic stellate cell activity via the EP4 receptor. Pancreas. 2013 Apr; 42(3):467-74.
    View in: PubMed
    Score: 0.004
  107. AACR Cancer Progress Report 2012. Clin Cancer Res. 2012 Nov 01; 18(21 Suppl):S1-100.
    View in: PubMed
    Score: 0.004
  108. Genetic polymorphisms in MicroRNA-related genes as predictors of clinical outcomes in colorectal adenocarcinoma patients. Clin Cancer Res. 2012 Jul 15; 18(14):3982-91.
    View in: PubMed
    Score: 0.004
  109. Ensuring quality cancer care: a follow-up review of the Institute of Medicine's 10 recommendations for improving the quality of cancer care in America. Cancer. 2012 May 15; 118(10):2571-82.
    View in: PubMed
    Score: 0.004
  110. APOBEC3G promotes liver metastasis in an orthotopic mouse model of colorectal cancer and predicts human hepatic metastasis. J Clin Invest. 2011 Nov; 121(11):4526-36.
    View in: PubMed
    Score: 0.004
  111. The role of chemokines in intestinal inflammation and cancer. Curr Opin Pharmacol. 2009 Dec; 9(6):688-96.
    View in: PubMed
    Score: 0.003
  112. Peroxisome proliferator-activated receptor beta/delta expression and activation in lung cancer. Am J Respir Cell Mol Biol. 2008 Dec; 39(6):689-96.
    View in: PubMed
    Score: 0.003
  113. Inhibition of epidermal growth factor receptor signaling elevates 15-hydroxyprostaglandin dehydrogenase in non-small-cell lung cancer. Cancer Res. 2007 Jun 15; 67(12):5587-93.
    View in: PubMed
    Score: 0.003
  114. Priorities in colorectal cancer research: recommendations from the Gastrointestinal Scientific Leadership Council of the Coalition of Cancer Cooperative Groups. J Clin Oncol. 2007 Jun 01; 25(16):2313-21.
    View in: PubMed
    Score: 0.003
  115. Extracellular signal-regulated kinase is a target of cyclooxygenase-1-peroxisome proliferator-activated receptor-delta signaling in epithelial ovarian cancer. Cancer Res. 2007 Jun 01; 67(11):5285-92.
    View in: PubMed
    Score: 0.003
  116. Requirement of phospholipase D1 activity in H-RasV12-induced transformation. Proc Natl Acad Sci U S A. 2005 Feb 01; 102(5):1638-42.
    View in: PubMed
    Score: 0.002
  117. Outcome of upper gastro-intestinal bleeding and use of ibuprofen versus paracetamol. Pharm World Sci. 2004 Dec; 26(6):319-23.
    View in: PubMed
    Score: 0.002
  118. Novel agents in the treatment of lung cancer: conference summary statement. Clin Cancer Res. 2004 Jun 15; 10(12 Pt 2):4199s-4204s.
    View in: PubMed
    Score: 0.002
  119. New avenues for the prevention of colorectal cancer: targeting cyclo-oxygenase-2 activity. Best Pract Res Clin Gastroenterol. 2002 Dec; 16(6):945-56.
    View in: PubMed
    Score: 0.002
  120. Controversies in COX-2 selective inhibition. J Rheumatol. 2002 Jul; 29(7):1501-10.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.